Resbiotic Raises $14.5M for Lung-Health Probiotic, Expansion

The latest microbiome company to raise funding, resbiotic offers what it says is the first clinically tested supplement targeting the “gut–lung” axis

Resbiotic Nutrition has raised a total of $14.5 million, including an $8 million Series A round, for gut microbiome supplements, including a flagship product for lung health. 

Sororibus Capital and Biostack Ventures supported the Series A round, the company said. The company didn’t disclose the source of the rest of its funding.

A physician-founded company, resbiotic says it plans to use the new funding to grow its product portfolio, scale retail and ecommerce distribution, and strengthen its B2B ingredient and formulations business.

The Birmingham, Alabama-based company is known for its flagship “resB Lung Support Probiotic,” which it bills as the first clinically tested supplement targeting the “gut–lung” axis. 

The company is extending its research-driven approach across what it calls the “Gut-X Axis,” a platform connecting gut health to whole-body outcomes to address chronic health issues. In addition to its lung-health probiotic, Resbiotic also sells prebiotics, probiotics and postbiotics designed to support metabolic health, women’s health, bone and joint health, and weight loss. 

“With res, we are setting a new standard in the supplement industry — products that are not only rooted in rigorous science but also accessible to people everywhere,” said resbiotic founder and CEO Dr. C. Vivek Lal. “By combining robust preclinical testing and clinical trials at the product level with a vertically integrated R&D model, we ensure our formulations deliver real, measurable benefits.”

Resbiotic’s products are sold on its website and nationwide at Walmart. The company also says it’s seeing growth in its B2B arm, which develops proprietary formulations and novel microbiome-based ingredients for use in industry collaborations. 

The funding announcement comes as the gut microbiome space continues to attract investors amid the longevity and healthspan boom. 

Viome, which offers at-home microbiome tests, has raised over $300 million to date, including a $25 million Series D round last year. Pendulum Therapeutics, a probiotics maker backed by Halle Berry, raised $54 million in a Series C round in 2023, bringing its total amount of VC funding raised at that time to $111 million.